Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Proteasome inhibitors act as bifunctional antagonists of human immunodeficiency virus type 1 latency and replication

24 Oct 2013

Abstract excerpt

BACKGROUND: Existing highly active antiretroviral therapy (HAART) effectively controls viral replication in human immunodeficiency virus type 1 (HIV-1) infected individuals but cannot completely eradicate the infection, at least in part due to the persistence of latently infected cells. One strategy that is being actively pursued to eliminate the latent aspect of HIV-1 infection involves therapies combining...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV/AIDS drug development and treatment
Share to HIV Research and Treatment
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24156270
DOI: 10.1186/1742-4690-10-120

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Proteasome inhibitors act as bifunctional antagonists of human immunodeficiency virus type 1 latency and replicationPMID 24156270Read ↗

HIV-1 Latency and Viral Reservoirs: Existing Reversal Approaches and Potential Technologies, Targets, and Pathways Involved in HIV Latency StudiesSemantic proximity Read ↗

Curing HIV: Pharmacologic Approaches to Target HIV-1 LatencySemantic proximity Read ↗

Proviral Latency, Persistent Human Immunodeficiency Virus Infection, and the Development of Latency Reversing AgentsSemantic proximity Read ↗

Targeting HIV latency: pharmacologic strategies toward eradicationSemantic proximity Read ↗

Infection with a newly designed dual fluorescent reporter HIV-1 effectively identifies latently infected CD4+ T cellsSemantic proximity Read ↗

Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategiesSemantic proximity Read ↗

Genome-wide CRISPR screens identify combinations of candidate latency reversing agents for targeting the latent HIV-1 reservoirSemantic proximity Read ↗

The Effect of JAK1/2 Inhibitors on HIV Reservoir Using Primary Lymphoid Cell Model of HIV LatencySemantic proximity Read ↗

The multifaceted nature of HIV latencySemantic proximity Read ↗

HIV latency: experimental systems and molecular modelsSemantic proximity Read ↗

A broad drug arsenal to attack a strenuous latent HIV reservoirSemantic proximity Read ↗

Ex vivo analysis identifies effective HIV-1 latency–reversing drug combinationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.